Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
Ironwood Pharmaceuticals, Inc. - Class A (IRWD)
Last ironwood pharmaceuticals, inc. - class a earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ironwoodpharma.com
Company Research
Source: Business Wire
– Feedback from recent FDA interaction indicates that a confirmatory Phase 3 trial evaluating apraglutide in SBS-IF is needed to seek approval –– Company has engaged Goldman Sachs & Co. LLC to explore strategic alternatives – BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that, based on a recent discussion with the U.S. Food and Drug Administration (FDA), a confirmatory Phase 3 trial is needed to seek approval of apraglutide for patients with short bowel syndrome (SBS) with intestinal failure (IF) who are dependent on parenteral support. While continuing to advance apraglutide, Ironwood has engaged Goldman Sachs & Co. LLC to explore strategic alternatives for the company to maximize value for stockholders.Apraglutide is a once weekly, long-acting synthetic GLP-2 analog with the potential to treat a ra
Show less
Read more
Impact Snapshot
Event Time:
IRWD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRWD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRWD alerts
High impacting Ironwood Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
IRWD
News
- Ironwood Pharmaceuticals (NASDAQ:IRWD) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- What Catalysts Are Shaping the Changing Narrative for Ironwood Pharmaceuticals? [Yahoo! Finance]Yahoo! Finance
- Ironwood Pharmaceuticals: Today's Gains Seem Sustainable After Disastrous First Half Of 2025 [Seeking Alpha]Seeking Alpha
- Ironwood Pharmaceuticals (NASDAQ:IRWD) had its price target raised by analysts at Wells Fargo & Company from $1.00 to $3.00. They now have an "equal weight" rating on the stock.MarketBeat
- Ironwood Pharmaceuticals Non-GAAP EPS of $0.24 beats by $0.12, revenue of $122.06M beats by $46.36M [Seeking Alpha]Seeking Alpha
IRWD
Earnings
- 11/10/25 - Beat
IRWD
Sec Filings
- 12/17/25 - Form 4
- 11/26/25 - Form 8-K
- 11/19/25 - Form 4
- IRWD's page on the SEC website